ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pirtobrutinib

Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.

Drug pagePirtobrutinib: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 6, 202530 company-led studies, 12 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly2811 open or runningphase 4since Mar 6, 2025Nov 6, 2018Oct 2027phase 3 · NCT05254743
AstraZenecaits history only10 open or runningphase 2since Jan 21, 2025Jan 21, 2025none ahead
Nurix Therapeuticsits history only11 open or runningphase 3since Mar 31, 2026Mar 31, 2026Oct 2029phase 3 · NCT07516093

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 6, 2018.

  1. Jul 15, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04965493 · 600 enrolled · United States, Australia, Belgium and more
  2. Jul 28, 2021Named pirtobrutinibINNProposed as its International Nonproprietary Name in WHO's List 125 · before, LOXO-305
  3. Aug 24, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05023980 · 282 enrolled · United States, Australia, Austria and more
  4. Oct 22, 20212 phase 1 studies in Healthy VolunteersNCT05134350, NCT05134337
  5. Jan 3, 2022Phase 1 study in HealthyNCT05176314 · 32 enrolled · United States
  6. Feb 15, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05254743 · 737 planned · United States, Argentina, Australia and more
  7. Oct 24, 2023Phase 2 study in Multiple SclerosisNCT06104683 · United States, Puerto Rico
  8. Nov 30, 2023Phase 1 study in HealthyNCT06165146 · 16 enrolled · United States
  9. Dec 11, 20239 phase 1 studiesNCT06190691, NCT06190678, NCT06194214 and 6 more
  10. Feb 6, 2024Phase 1 study in HealthyNCT06258174 · 28 enrolled · United States
  11. Sep 6, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06588478 · 249 planned · United States, Australia, Belgium and more
  12. Dec 3, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06721013 · 68 planned · United States, China, Denmark and more
  13. Mar 6, 20252 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT06876662, NCT06876649
  14. Aug 29, 2025Phase 2 study in Lymphoma, Non-HodgkinNCT07162181 · 13 enrolled · China
  15. Oct 16, 2025Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07218341 · 150 planned · United States, Australia, Austria and more

Ahead

  1. Oct 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05254743
  2. Nov 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellNCT04662255
  3. Feb 2028Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06721013
  4. Jun 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06588478

TargetBeta

BTK →read by rule
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 28 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more4RecruitingMay 2030150
NCT07162181Lymphoma, Non-Hodgkin · China2Active, not recruitingMay 203013
NCT06876662Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more4RecruitingMay 2030279
NCT06876649Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more4RecruitingMay 2030787
NCT06721013Purpura, Thrombocytopenic, Idiopathic · United States, China, Denmark and more2RecruitingFeb 202868
NCT06588478Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more2RecruitingJun 2028249
NCT06258174Healthy · United States1CompletedDec 22, 202128
NCT06215521Healthy · United States1CompletedMar 31, 202131
NCT06215430Healthy · United States1CompletedApr 15, 202116
NCT06194214Healthy · United States1CompletedJun 9, 202116
NCT06181006Healthy · United States1CompletedDec 1, 202024
NCT06180980Healthy · United States1CompletedMar 8, 202120
NCT06180967Healthy · United States1CompletedOct 20, 202015
NCT06180954Healthy · United States1CompletedNov 6, 20209
NCT06190691Hepatic Insufficiency · United States1CompletedDec 30, 202136
NCT06190678Renal Insufficiency · United States1CompletedJun 4, 202116
NCT06165146Healthy · United States1CompletedDec 30, 202016
NCT06104683Multiple Sclerosis · United States, Puerto Rico2WithdrawnJan 16, 20260
NCT05254743Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingOct 2027737
NCT05176314Healthy · United States1CompletedApr 20, 202232
NCT05134350Healthy Volunteers · United States1CompletedMar 23, 202010
NCT05134337Healthy Volunteers · United States1CompletedOct 30, 202027
NCT05023980Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingJul 11, 2025282
NCT04965493Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3Active, not recruitingOct 2026600
NCT04849416Leukemia, Lymphoid · China2CompletedApr 10, 202387
NCT04666038Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3Active, not recruitingAug 29, 2023238
NCT04662255Lymphoma, Mantle-Cell · United States, Australia, Austria and more3Active, not recruitingNov 2027500
NCT03740529Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more2CompletedJan 27, 2025803

How it is read

Names in the registry

  • “Pirtobrutinib”, 26 entries
  • “LOXO-305”, 3 entries
  • “[14C]-LOXO-305”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.